Bonneaud and colleagues unraveled that targeting MCL-1 via BH3 mimetic, an antagonist to various BCL-2 congeners, including MCL-1, can mitigate the invasion of cancer cells and inhibit their tumor-promoting function. Here, MCL1 is linked to cancer.